Myomo (NYSEAMERICAN:MYO) Downgraded to Neutral at Roth Capital
Roth Capital downgraded shares of Myomo (NYSEAMERICAN:MYO) from a buy rating to a neutral rating in a research note released on Wednesday morning, Zacks.com reports.
A number of other equities research analysts have also weighed in on MYO. Ascendiant Capital Markets assumed coverage on shares of Myomo in a research note on Tuesday, July 30th. They set a buy rating and a $2.00 target price on the stock. Zacks Investment Research lowered shares of Myomo from a hold rating to a sell rating in a research note on Saturday.
Myomo stock traded down $0.03 during trading hours on Wednesday, reaching $0.51. The stock had a trading volume of 58,299 shares, compared to its average volume of 135,937. Myomo has a 52 week low of $0.43 and a 52 week high of $2.01.
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis used for the purpose of supporting a patient's weak or deformed arm to enable and improve functional activities of daily living, ADLs, in the home and community.
Featured Story: What is a good rate of return for a mutual fund?
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.